Thomas H Ehrich

Content from this author

• Why new FTO techniques are critical in the mRNA patent litigation landscape
  Featured in Special Report 2023 Q2: New Frontiers of Pharma and Biotech IP Strategy

• mRNA vaccines: how to navigate the freedom-to-operate maze